CBLB endonuclease variants, compositions, and methods of use
The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
1. A fusion polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 13, wherein the polypeptide binds to and cleaves a target site in a human Cbl lymphoma proto-oncogene B (CBLB) set forth in SEQ ID NO: 22.
2. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 13.
3. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 13.
4. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 14.
5. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 15.
6. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 16.
7. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 17.
8. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 18.
9. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 19.